{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:31:13Z","timestamp":1790771473066,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dysthyroid optic neuropathy (DON) is a serious threatening vision loss in Graves\u2019 ophthalmopathy (GO). Although the European Group on Graves\u2019 Ophthalmopathy (EUGOGO) recommend intravenous methylprednisolone therapy for first line treatment, some characteristics predicting the response are still inconclusive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To study the efficacy of intravenous pulse methylprednisolone (IVMP) in treating dysthyroid optic neuropathy (DON) and to identify factors predicting poor response to the treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients diagnosed with DON between January 2010 and December 2021 at Rajavithi Hospital, Thailand, receiving IVMP 1\u2009g\/ day for 3 consecutive days were analyzed. The efficacy at 1\u2009week and 3, 6, 12-months in terms of improvement of best corrected visual acuity (BCVA) and proptosis were compiled.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the entire 57 DON cases that received IVMP, 50.9% gained at least 0.2 Logarithm of the Minimum Angle of Resolution (logMAR) at 1\u2009week, and the improvement from initial to 1-week BCVA was 0.63\u2009\u00b1\u20090.63 logMAR (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and the decrease in proptosis was 1.8\u2009\u00b1\u20091.36\u2009mm (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The remaining 23 orbits underwent orbital decompression and were excluded from the long-term efficacy analysis. In the last 12-months\u2019 follow-up time, there was an improvement of BCVA (0.53\u2009\u00b1\u20090.47 logMAR) and proptosis (0.59\u2009\u00b1\u20090.66\u2009mm) (both<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). At last visit, there was an improvement of BCVA (0.2 logMAR) and proptosis (2\u2009mm) in 76.5, and 5.9% respectively. Significant predictive factors of poor treatment response were age\u2009\u2265\u200955\u2009years (odds ratio [OR]: 8.28, 95% confidence interval [CI]: 1.368\u201350.121,<jats:italic>p<\/jats:italic>\u2009=\u20090.021); longer onset duration before treatment (OR: 5.10, 95%CI: 1.061\u201324.501,<jats:italic>p<\/jats:italic>\u2009=\u20090.042); and proptosis at baseline (OR: 9.31, 95%CI: 1.872\u201346.280,<jats:italic>p<\/jats:italic>\u2009=\u20090.006). The strongest risk factor for predicting poor response to IVMP was poor initial visual acuity (OR: 10.26, 95%CI: 1.363\u201377.234,<jats:italic>p<\/jats:italic>\u2009=\u20090.024).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>IVMP is effective for both short- and long-term treatment to improve visual acuity greater than proptosis. Older age, longer disease duration, poor initial visual acuity, and proptotic orbits were identified as risk factors for predicting poor response to IVMP treatment in Thai population. DON patients having those risk factors should be suspected, and treated early with IVMP to preserve their future vision.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12886-023-02789-5","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T11:03:03Z","timestamp":1674471783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7153-0813","authenticated-orcid":false,"given":"Parinee","family":"Kemchoknatee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duanghathai","family":"Tangon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thansit","family":"Srisombut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"issue":"11","key":"2789_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/S0161-6420(88)32978-7","volume":"95","author":"JM Neigel","year":"1988","unstructured":"Neigel JM, Rootman J, Belkin RI, Nugent RA, Drance SM, Beattie CW, et al. Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology. 1988;95(11):1515\u201321.","journal-title":"Ophthalmology"},{"issue":"5","key":"2789_CR2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1097\/SCS.0b013e31825e3acf","volume":"23","author":"P Cascone","year":"2012","unstructured":"Cascone P, Rinna C, Reale G, Calvani F, Iannetti G. Compression and stretching in graves orbitopathy: emergency orbital decompression techniques. J Craniofac Surg. 2012;23(5):1430\u20133.","journal-title":"J Craniofac Surg"},{"key":"2789_CR3","first-page":"477","volume":"92","author":"GB Bartley","year":"1994","unstructured":"Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477\u2013588.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"3","key":"2789_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40618-020-01361-y","volume":"44","author":"PJ Dolman","year":"2021","unstructured":"Dolman PJ. Dysthyroid optic neuropathy: evaluation and management. J Endocrinol Investig. 2021;44(3):421\u20139.","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"2789_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12886-020-1314-8","volume":"20","author":"M Tagami","year":"2020","unstructured":"Tagami M, Honda S, Azumi A. Preoperative clinical factors and visual outcomes following orbital decompression with dysthyroid optic neuropathy. BMC Ophthalmol. 2020;20(1):30.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"2789_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European thyroid association\/European group on Graves' Orbitopathy guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal. 2016;5(1):9\u201326.","journal-title":"European Thyroid Journal"},{"issue":"4S Suppl 1","key":"2789_CR7","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1097\/IOP.0000000000001146","volume":"34","author":"P Saeed","year":"2018","unstructured":"Saeed P, Tavakoli Rad S, Bisschop P. Dysthyroid Optic Neuropathy. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1):S60\u2013s7.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"7","key":"2789_CR8","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0161-6420(89)32784-9","volume":"96","author":"JR Guy","year":"1989","unstructured":"Guy JR, Fagien S, Donovan JP, Rubin ML. Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology. 1989;96(7):1048\u201352 discussion 52\u20133.","journal-title":"Ophthalmology"},{"issue":"5","key":"2789_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2013.0445","volume":"24","author":"N Curr\u00f2","year":"2014","unstructured":"Curr\u00f2 N, Covelli D, Vannucchi G, Campi I, Pirola G, Simonetta S, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014;24(5):897\u2013905.","journal-title":"Thyroid"},{"issue":"3","key":"2789_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","volume":"63","author":"IM Wakelkamp","year":"2005","unstructured":"Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves\u2019 ophthalmopathy? A randomized controlled trial Clin Endocrinol (Oxf). 2005;63(3):323\u20138.","journal-title":"A randomized controlled trial Clin Endocrinol (Oxf)"},{"issue":"9","key":"2789_CR11","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41433-020-0897-x","volume":"34","author":"A Garip Kuebler","year":"2020","unstructured":"Garip Kuebler A, Wiecha C, Reznicek L, Klingenstein A, Halfter K, Priglinger S, et al. Evaluation of medical and surgical decompression in patients with dysthyroid optic neuropathy. Eye (Lond). 2020;34(9):1702\u20139.","journal-title":"Eye (Lond)"},{"issue":"8","key":"2789_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362(8):726\u201338.","journal-title":"N Engl J Med"},{"issue":"8","key":"2789_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","volume":"129","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, et al. Cigarette smoking and treatment outcomes in graves ophthalmopathy. Ann Intern Med. 1998;129(8):632\u20135.","journal-title":"Ann Intern Med"},{"issue":"12","key":"2789_CR14","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1136\/bjophthalmol-2014-306463","volume":"99","author":"L Xing","year":"2015","unstructured":"Xing L, Ye L, Zhu W, Shen L, Huang F, Jiao Q, et al. Smoking was associated with poor response to intravenous steroids therapy in graves\u2019 ophthalmopathy. Br J Ophthalmol. 2015;99(12):1686.","journal-title":"Br J Ophthalmol"},{"key":"2789_CR15","first-page":"41","volume":"65","author":"RM Day","year":"1967","unstructured":"Day RM, Carroll FD. Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction. Trans Am Ophthalmol Soc. 1967;65:41\u201351.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"2789_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/bjo.2006.110932","volume":"91","author":"CM Dayan","year":"2007","unstructured":"Dayan CM, Dayan MR. Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity? Br J Ophthalmol. 2007;91(4):409\u201310.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"2789_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00002341-200205000-00005","volume":"18","author":"JA Giaconi","year":"2002","unstructured":"Giaconi JA, Kazim M, Rho T, Pfaff C. CT scan evidence of dysthyroid optic neuropathy. Ophthalmic Plast Reconstr Surg. 2002;18(3):177\u201382.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"2789_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3341\/kjo.2012.26.2.73","volume":"26","author":"C Jeon","year":"2012","unstructured":"Jeon C, Shin JH, Woo KI, Kim YD. Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy. Korean J Ophthalmol. 2012;26(2):73\u20139.","journal-title":"Korean J Ophthalmol"},{"issue":"4","key":"2789_CR19","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u2013g67.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2789_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/jop.2005.21.328","volume":"21","author":"RH Hart","year":"2005","unstructured":"Hart RH, Kendall-Taylor P, Crombie A, Perros P. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J Ocul Pharmacol Ther. 2005;21(4):328\u201336.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"2789_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1076\/orbi.20.4.275.2612","volume":"20","author":"M Ph Mourits","year":"2001","unstructured":"Ph Mourits M, Kalmann R, Sasim IV. Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy. Orbit. 2001;20(4):275\u201380.","journal-title":"Orbit"},{"issue":"2","key":"2789_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320\u201332.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 3","key":"2789_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1042\/bj20021856","volume":"371","author":"JD Croxtall","year":"2003","unstructured":"Croxtall JD, Gilroy DW, Solito E, Choudhury Q, Ward BJ, Buckingham JC, et al. Attenuation of glucocorticoid functions in an Anx-A1\u2212\/\u2212 cell line. Biochem J. 2003;371(Pt 3):927\u201335.","journal-title":"Biochem J"},{"key":"2789_CR24","doi-asserted-by":"publisher","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves' Orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2789_CR25","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2789_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.beem.2011.10.005","volume":"26","author":"JH Lazarus","year":"2012","unstructured":"Lazarus JH. Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab. 2012;26(3):273\u20139.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2789_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","volume":"38","author":"P Perros","year":"1993","unstructured":"Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol. 1993;38(4):367\u201372.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"2789_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5603\/EP.a2016.0018","volume":"67","author":"P Mi\u015bkiewicz","year":"2016","unstructured":"Mi\u015bkiewicz P, Rutkowska B, Jab\u0142o\u0144ska A, Krzeski A, Trautsolt-Jeziorska K, K\u0119cik D, et al. Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy. Endokrynol Pol. 2016;67(2):166\u201373.","journal-title":"Endokrynol Pol"},{"issue":"8","key":"2789_CR29","first-page":"568","volume":"20","author":"RL Anderson","year":"1989","unstructured":"Anderson RL, Tweeten JP, Patrinely JR, Garland PE, Thiese SM. Dysthyroid optic neuropathy without extraocular muscle involvement. Ophthalmic Surg. 1989;20(8):568\u201374.","journal-title":"Ophthalmic Surg"},{"issue":"20","key":"2789_CR30","first-page":"1572","volume":"95","author":"L Guo","year":"2015","unstructured":"Guo L, Yang G, Gu W, Jin N, Chen K, Du J, et al. Short-term efficacies of intravenous glucocorticoid therapy for moderate-to-severe Graves' ophthalmopathy. Zhonghua Yi Xue Za Zhi. 2015;95(20):1572\u20135.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"9","key":"2789_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic neuritis study group. N Engl J Med. 1992;326(9):581\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"2789_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/bjo.2006.094607","volume":"91","author":"D McKeag","year":"2007","unstructured":"McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, et al. Clinical features of dysthyroid optic neuropathy: a European group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007;91(4):455\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"2789_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/thy.1992.2.229","volume":"2","author":"WM Wiersinga","year":"1992","unstructured":"Wiersinga WM. Immunosuppressive treatment of Graves' ophthalmopathy. Thyroid. 1992;2(3):229\u201333.","journal-title":"Thyroid"},{"issue":"2","key":"2789_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1006\/exer.1997.0353","volume":"65","author":"HB Burch","year":"1997","unstructured":"Burch HB, Lahiri S, Bahn RS, Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy. Exp Eye Res. 1997;65(2):311\u20136.","journal-title":"Exp Eye Res"},{"issue":"7","key":"2789_CR35","first-page":"2244","volume":"82","author":"LC Hofbauer","year":"1997","unstructured":"Hofbauer LC, M\u00fchlberg T, K\u00f6nig A, Heufelder G, Schworm HD, Heufelder AE. Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves' ophthalmopathy undergoing orbital radiotherapy. J Clin Endocrinol Metab. 1997;82(7):2244\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2789_CR36","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.87.6.773","volume":"87","author":"A Eckstein","year":"2003","unstructured":"Eckstein A, Quadbeck B, Mueller G, Rettenmeier AW, Hoermann R, Mann K, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol. 2003;87(6):773\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"2789_CR37","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.beem.2011.09.004","volume":"26","author":"L Bartalena","year":"2012","unstructured":"Bartalena L. Prevention of Graves\u2019 ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):371\u20139.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2789_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1089\/thy.1999.9.297","volume":"9","author":"R Lu","year":"1999","unstructured":"Lu R, Wang P, Wartofsky L, Sutton BD, Zweier JL, Bahn RS, et al. Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. Thyroid. 1999;9(3):297\u2013303.","journal-title":"Thyroid"},{"issue":"2","key":"2789_CR39","first-page":"542","volume":"79","author":"AW Kung","year":"1994","unstructured":"Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab. 1994;79(2):542\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2789_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4103\/2230-8210.152770","volume":"19","author":"A Roy","year":"2015","unstructured":"Roy A, Dutta D, Ghosh S, Mukhopadhyay P, Mukhopadhyay S, Chowdhury S. Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves' orbitopathy: a randomized controlled trial. Indian J Endocrinol Metab. 2015;19(3):351\u20138.","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"2789_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12902-018-0240-8","volume":"18","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang S, Zhang Y, Liu X, Gu H, Zhong S, et al. A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy. BMC Endocr Disord. 2018;18(1):13.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2789_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2265.1986.tb03590.x","volume":"25","author":"C Balazs","year":"1986","unstructured":"Balazs C, Kiss E, Le\u00f6vey A, Farid NR. The immunosuppressive effect of methimazole on cell-mediated immunity is mediated by its capacity to inhibit peroxidase and to scavenge free oxygen radicals. Clin Endocrinol. 1986;25(1):7\u201316.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2789_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/bjo.83.4.463","volume":"83","author":"R Kalmann","year":"1999","unstructured":"Kalmann R, Mourits MP. Diabetes mellitus: a risk factor in patients with Graves' orbitopathy. Br J Ophthalmol. 1999;83(4):463\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"2789_CR44","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.4103\/ijo.IJO_1443_19","volume":"68","author":"LB Ramamurthy","year":"2020","unstructured":"Ramamurthy LB, Rangarajan V, Srirao N, Malini B, Bansal R, Yuvarajan K. Severity of thyroid eye disease and type-2 diabetes mellitus: is there a correlation? Indian J Ophthalmol. 2020;68(6):1127\u201331.","journal-title":"Indian J Ophthalmol"},{"issue":"4","key":"2789_CR45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/IOP.0000000000001871","volume":"37","author":"S Rath","year":"2021","unstructured":"Rath S, Pattnaik M, Tripathy D, Mohapatra S, Panigrahy B, Ali MH. Sight-threatening thyroid eye disease: role of diabetes mellitus and interaction with other risk factors. Ophthalmic Plast Reconstr Surg. 2021;37(4):352\u201360.","journal-title":"Ophthalmic Plast Reconstr Surg"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-023-02789-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-023-02789-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-023-02789-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T06:42:22Z","timestamp":1701758542000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-023-02789-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2789"],"URL":"https:\/\/doi.org\/10.1186\/s12886-023-02789-5","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Rajavithi Hospital (certificate number: 136\/2564). The protocol adhered to the provisions of the Declaration of Helsinki. All patients provided written informed consent before their data was collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have no conflicts of interest to disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}